A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog Some good news for those on NOAC. New drug - Clinical trials were stopped early because of good outcomes. Not sure when it will be ready for patients. [www.acc.org] Press Release: Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation. https://www.afibbers.org/forum/read.php?9,193411,193411#msg-193411 Sun, 13 Sep 2026 12:50:33 +0000 Phorum 5.2.23 https://www.afibbers.org/forum/read.php?9,193411,193665#msg-193665 Re: A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog https://www.afibbers.org/forum/read.php?9,193411,193665#msg-193665
Jim]]> mjamesone AFIBBERS FORUM Sat, 16 Dec 2023 19:02:25 +0000 https://www.afibbers.org/forum/read.php?9,193411,193411#msg-193411 A Multicenter, RandomiZed, Active-ControLled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab Compared With Open-Label Rivaroxaban in Patients With Atrial Fibrillation - American College of Cardiolog https://www.afibbers.org/forum/read.php?9,193411,193411#msg-193411
[www.acc.org]

Press Release: Anthos Therapeutics’ Novel Dual Acting Factor XI / XIa Inhibitor, Abelacimab 150 mg, Demonstrated a 67% Reduction in the Primary Endpoint of Major or Clinically Relevant Non-Major Bleeding Compared with Rivaroxaban in Patients with Atrial Fibrillation.]]> sldabrowski AFIBBERS FORUM Tue, 28 Nov 2023 03:13:51 +0000